Serotype-Specific Pneumococcal Status prior to PCV 13 Administration in Children and Adolescents with Inflammatory Bowel Disease
Aleksandra Banaszkiewicz, Brygida Targonska, KInga Kowalska-Duplaga, Katarzyna Karolewska-Bochenek, Agnieszka Sieczkowska, Agnieszka Gawronska, Urszula Grzybowska-Chlebowczyk, Elzbieta Krzesiek, Izabella Lazowska-Przeorek, Maria Kotowska, Edyta Sienkiewicz, Jaroslaw Walkowiak, Hanna Gregorek, Andrzej Radzikowski, Piotr Albrecht Pol J Microbiol 2016; 65 (1): ICID: 1197279 Article type: Short communication IC™ Value: 6.00
Abstract provided by Publisher
The aim of this study was to evaluate the serotype-specific pneumococcal status of children and adolescents with inflammatory bowel disease (IBD) who were naïve to pneumococcal vaccination before administering the 13-valent pneumococcal conjugate vaccine (PCV 13). This was an open, prospective study on children and adolescents aged 5–18 years who had IBD and were naïve to pneumococcal vaccination. A single dose of PCV 13 was administered to each patient. The geometric mean concentrations (GMCs) were measured for all 13 serotypes. A total of 122 subjects completed the study. Prevaccination GMCs ranged from 0.55 μg/ml (serotype 4) to 4.26 μg/ml (serotype 19A). Prior to the administration of PCV 13, high GMCs were detected in older children and adolescents who had IBD and were naïve to pneumococcal vaccination.